PBC in 2026: Is “Biochemical Response” No Longer Enough?: GastroAGI| August 2026

Topic: Evolving standards of care in primary biliary cholangitis (PBC), with increasing emphasis on ALP normalisation, liver stiffness, second-line PPAR agonists, pruritus, and fatigue.

Key Takeaways

The treatment goal in PBC is broader than preventing cirrhosis. Progressive ductopenia can cause liver failure even without advanced fibrosis; therefore, both fibrosis progression and bile-duct loss matter.

UDCA remains the foundation of therapy and should usually be continued even when biochemical response is incomplete. Correct weight-based dosing—around 13–15 mg/kg/day—is essential.

“Incomplete response” does not mean UDCA has failed. These patients still benefit from UDCA but may require additional therapy to further reduce disease progression.

ALP normalization is emerging as the ideal target. Risk appears to increase as ALP rises above normal, while even a bilirubin that is rising within the laboratory “normal range” may signal worsening prognosis.

Liver stiffness measurement adds another dimension to risk. A younger patient with persistent biochemical abnormalities and increasing liver stiffness should prompt earlier therapeutic escalation.

PPAR agonists are changing second-line treatment. Seladelpar and elafibranor improve cholestatic biochemistry, while bezafibrate remains an effective off-label option in some regions.

Mechanism made simple:

PPAR activation → ↓ bile-acid synthesis + ↑ protective phospholipid secretion → less bile-duct toxicity → reduced inflammation and potentially fibrosis.

PPAR agonists may also improve pruritus, possibly through modulation of pruritogenic pathways including IL-31.

Fatigue is distinct from itch and may involve central, muscular, inflammatory and mitochondrial mechanisms. Early signals suggest PPAR agonists may improve fatigue, although the mechanism remains uncertain.

GastroAGI Bottom Line

Modern PBC management should move from “Did the patient respond?” to “Have we controlled disease progression and improved how the patient feels?” Persistent abnormal ALP plus younger age, rising bilirubin or increased liver stiffness should increasingly trigger consideration of treatment escalation.